Introduction
============

Diffuse large B-cell lymphomas (DLBCL) are the most frequent B cell Non-Hodgkin's lymphomas. Diagnosis relies at present on morphological, immune-phenotypic and laboratory parameters. Clinically, the International Prognostic Index (IPI; age, tumor stage, serum lactate dehydrogenase concentration, performance status, and the number of extranodal disease sites) ([@b22-cin-03-399]) is often used to predict outcome in DLBCL. On the molecular level, gene expression signatures have been defined that predict outcome in DLBCL independent of the IPI ([@b16-cin-03-399]).

[@b1-cin-03-399] investigated the gene expression patterns of "diffuse large DLBCL, follicular lymphoma and chronic lymphatic leukemia. They identified two novel distinct types of the DLBCL by gene expression profiling. The "activated B cell-like DLBCL"(ABC) group has a lower overall survival rate than the "germinal centre B cell-like DLBCL" (GCB) group. [@b25-cin-03-399] applied their class discovery method ISIS on a subset of 62 samples and 4026 clones of the data by [@b1-cin-03-399] and confirmed for these data the two entities ABC and GCB. The survival analysis of [@b16-cin-03-399], assigned several genes to gene expression signatures and based on this an outcome predictor of survival. The constituents are the "Germinal-center B-cell signature", "MHC class II signature", "Lymph-node signature", "Proliferation signature" and the gene "BMP6". The predictor has a greater prognostic power in classifying patients into risk groups than the IPI ([@b22-cin-03-399]). Starting with 36 well known DLBCL prognosis genes from the literature, [@b9-cin-03-399] found a six gene based outcome predictor and applied it to the data sets of [@b1-cin-03-399] and [@b16-cin-03-399]. The latter one is an ongoing study and thus an extension and revision of the old data from [@b16-cin-03-399] was possible for us (see Material and Methods).

In this study we investigate first the robustness of the data ([@b16-cin-03-399]) with respect to advanced and more appropriate normalization methods. For that, "loess" and "scale" are performed on the data set, as we are aware, for the first time and the results are discussed. Next, unbiased statistical classification analysis confirms for this enlarged data set the classical subgroups ABC DLBCL and GCB DLBCL independent from hierarchical clustering. Furthermore it supports those subgroups being homogeneous entities in the data.

Our analysis includes the expression values for the above 36 DLBCL prognosis genes and we apply more adequate tools from the Bioconductor library ([@b5-cin-03-399]) to derive better predictors than e.g. the six-spot predictor found by ([@b9-cin-03-399]). Moreover, we identify and demonstrate that expression of early and late cell cycle genes distinguishes well the pathological entities ABC and GCB DLBCL.

Finally, we show that the most significant gene expression differences found including cell cycle genes, classical marker genes and all best separating genes are integrated into a compact key regulatory network with clear expression differences between both diffuse large B-cell-lymphoma subgroups. This finding is confirmed comparing the average distribution of genes on the Lymphochip and the connection distances between them in the human interactome as well as by confirming key gene expression differences found in our main data set from new analysis of further gene expression data by [@b18-cin-03-399]. A picture emerges where a central regulatory circuit tunes immune signatures, apoptotic and proliferation pathways in different ways between ABC and GCB DLBCL. The introduced methods can also be applied to other studies of gene expression analysis in cancer to establish improved prognosis predictors, identify regulatory circuits and for proper group classification.

Materials and Methods
=====================

Gene expression data and materials
----------------------------------

Patient samples were obtained after informed consent and were treated anonymously during microarray analysis. DLBCL lymph-node biopsies were either snap frozen, frozen in OCT or disaggregated and frozen as a viable cell suspension. DLBCL gene expression was measured with cDNA arrays containing genes preferentially expressed in lymphoid cells or genes known or presumed to be part of cancer development or immune function ("Lymphochip" microarrays ([@b2-cin-03-399])). Our array includes spots to measure individual exons of the same gene which may be expressed differently in both lymphoma subgroups.

Microarray procedures
---------------------

Fluorescent images of hybridized microarrays were obtained using a GenePix 4000 microarray scanner (Axon Instruments). Images were analysed with ScanAlyze (M. Eisen; <http://www.microarrays.org/software>), and fluorescence ratios (along with numerous quality control parameters; see ScanAlyze manual) were stored in a custom database. Single spots or areas of the array with obvious blemishes were flagged and excluded from subsequent analyses. Messenger RNA was extracted according to standard procedures ([@b17-cin-03-399]) from tumor biopsy specimens of DLBCL patients. All cDNA microarray analyses were performed using poly-(A)+ mRNA (Fast Track, Invitrogen). For each hybridization, fluorescent cDNA probes were prepared from an experimental mRNA sample (Cy5-labelled) and a reference mRNA sample (Cy3-labelled) consisting of a pool of nine lymphoma cell lines (Raji, Jurkat, L428, OCI-Ly3, OCI-Ly8, OCI-Ly1, SUDHL5, SUDHL6 and WSU1). The use of a common reference cDNA probe allows the relative expression of each gene to be compared across all samples.

The original data generated by [@b16-cin-03-399], in which the subgroups were defined by hierarchical clustering was provided to us by the authors. In our study we analyse an enlarged data set as follows: more patients (a total of 248 patients, each patient array included 12196 gene spots corresponding to 3717 genes), including a more recent classification. The outcome of this are 12.3% more ABC and 5.2% less GCB patients. 19 patients have been removed from the ABC and GCB groups. In detail, five ABC patients were removed from the earlier ABC classification, however, 14 other ones are now associated with it. From the earlier GCB group, 14 patients were assigned to other entities and 11 other patients were newly classified as GCB. Altogether, 25 patients were thus newly recruited into these two groups. Moreover, each spot is now analyzed in the new study individually. There was no pooling of data on datapoints (spots) as done in older analyses ([@b16-cin-03-399]). We further fully account for the changes in patients analysed (described above) by such an individual spot analysis. In summary this yielded about 3.3 times more data points per patient.

**Statistical analyses** were performed using the statistical software package R (R [@b14-cin-03-399]) and Bioconductor ([@b5-cin-03-399]). For normalization of gene expression data, methods such as vsn, loess and scaling methods were used. To detect differentially expressed genes, functions from the Bioconductor package "limma" were applied. Its special strength is the robust statistics based on linear models and a moderated t-test statistics including multiple testing correction methods ([@b19-cin-03-399], pp 397--420; [@b20-cin-03-399]). Based on diagnostic plots we chose gene expression normalization using within-array and between-array normalization methods. The within-array normalization "loess" ([@b29-cin-03-399], pp 141--152; [@b30-cin-03-399]) adjusts expression log-ratios in the way that they average to zero within each array to make genes on one array comparable to each other. We applied the "scale" method ([@b29-cin-03-399], pp 141--152; [@b30-cin-03-399]; [@b21-cin-03-399]) for between-array normalization. It scales log-ratios to have the same median-absolute-deviation (MAD) across arrays. By this, log-ratios are normalized to show similar variance across a batch of arrays.

**Unbiased class discovery** was performed using the ISIS method (*i*dentifying *s*plits w*i*th clear *s*eparation; [@b25-cin-03-399]). It searches for binary class distinctions in the gene expression levels in an unsupervised fashion. The diagonal linear discriminat score (DLD) quantifies for every found bipartition how strongly the two classes are separated. A maximum sample size of 150 patients for each ISIS run considered 3000 measurements and delivered 50 best separating genes.

**Cox regression hazard models** were done applying the R package "survival" ([@b3-cin-03-399]; [@b23-cin-03-399]), to calculate the influence of gene expression values on the survival time and Kaplan Meier estimates. The outcome predictor score is calculated with the coefficients of the Cox model and the gene expression values.

**Supervised class analyses** were performed using "Prediction Analysis of Microarrays" (PAM) ([@b24-cin-03-399]). PAM performs a nearest shrunken centroid method to identify a subset of genes that best characterizes samples as ABC or GCB DLBCL. It computes a standardized centroid for each class and shrinks the prototypes for a given classification error threshold. In the resulting list the obtained optimal (for the given error) shrunken centroid identifier is followed by the number of genes it contains. The chosen classifier is validated by ten-fold cross-validation.

Smaller gene sets typically show larger error rates. However, if almost equally good performing classifiers existed, we parsimoniously chose the one containing the smallest number of genes. The proposed best gene set used for our analysis had 31 spots (labelled by an 'x' character in [Fig. 2](#f2-cin-03-399){ref-type="fig"}).

**Protein association networks** were identified by the STRING database, version 6.3 ([@b26-cin-03-399]), of known and predicted proteinprotein interactions. It combines information from genomic context, experiments, other databases, co-expression and text-mining. Homology predictions transfer and extend these data further. We used the STRING database with a Bayesian confidence level of 0.400 (medium confidence) and a custom limit of 0 (only direct interactions of proteins are considered).

Results
=======

Improving prognosis prediction and separation of DLBCL subtypes
---------------------------------------------------------------

### Statistical validation of the DLBCL subgroups ABC DLBCL and GCB DLBCL

Both subgroups were originally introduced on the basis of gene expression profiling. There has been some suggestion that certain diffuse large B-cell lymphomas form a third group ([@b6-cin-03-399]). Furthermore, it was interesting to see whether this classification is also valid for this data set by an unsupervised classification method. To decide independently of any pre-clustering of specific marker genes whether there are two, three or even more lymphoma subgroups and whether they overlap with groups according to other group definitions (e.g. pathology). ISIS (see Materials and Methods) systematically investigates unsupervised all possible bipartitions of the gene expression data (excluding mediastinal lymphomas; see Materials and Methods) without prior knowledge of marker genes or signature pre-classification ([Fig. 1](#f1-cin-03-399){ref-type="fig"}). Nevertheless the bipartitions with the three highest separation scores support and identify the two pathological entities ABC and GCB. Distinct subgroups (splits) within the ABC or GCB entities are not validated by ISIS. In particular, no appropriate bipartition could be observed using previously putatively classified Type 3 patients and the ABC or GCB samples (data not shown). The precise separation into exactly these two subgroups is thus well supported even by an unbiased statistical method independent of predefined expression signatures.

### Survival prognosis detection on the updated data and after advanced normalization

The signatures by [@b16-cin-03-399] are independent from the clinical IPI score (see Introduction) and useful predictors within the low, medium and high IPI risk groups on their data set ([@b16-cin-03-399]). We now tested the performance of advanced normalization methods, namely the methods "loess" ([@b29-cin-03-399]; [@b30-cin-03-399]) and "scale" ([@b21-cin-03-399]; [@b29-cin-03-399]; [@b30-cin-03-399]) on our data set. The IPI score is considered here only as an independent and established clinical prognosis marker. On a normalized data set of 240 patients and considering all individual spots we utilised Kaplan Meier plots ([Fig. S1](#f4-cin-03-399){ref-type="supplementary-material"}) and reveal the good performance of the gene expression profiles ([@b16-cin-03-399]) also for this data set using the improved normalization procedure. The low risk IPI group in the renormalized data is not as well separated between the best and worst quartile as in [@b16-cin-03-399]. The separation of the high risk group is virtually unchanged. However, in the medium risk group a better separation was achieved by the renormalization and single spot analysis of the enlarged patient data. For the medium risk patients a better separation into high and low risk is particularly important for prognosis prediction. This method including the advanced normalization can also be applied to any other microarray data set.

### An improved six-spot predictor for survival prognosis comparing multi- and univariate analysis

The immune signature requires the measurement of gene expression for many genes. We investigated whether a combination of array spots achieves similar good classification. Multivariate analysis (4 spots results in [Table S1](#t3-cin-03-399){ref-type="table"} and [Table S2](#t4-cin-03-399){ref-type="table"}, they include immune genes) was computationally prohibitive for more than 4 spots. However, by univariate analysis we could systematically test the capability of gene expression values from individual spots to separate patients with good or bad prognosis in Kaplan-Meier plots. We considered for all three IPI classes the separation of best patient quartile with good prognosis from the worst patient quartile with poor prognosis. Using all genes and the 160 patients from the training-set we identified the spots predicting outcome best. Together, in a multivariate model, they form a predictor separating best and worst quartiles for all three IPI categories including the 80 patients from the validation-set. The five-spot-predictor considers different splicing forms in HLA-DRB5. Five spots (HLA-DPa, Brca, HLA-DQa, and two clones of HLA-DRB5; details in Suppl. Material) are about equal to the six gene predictor of [@b9-cin-03-399]. However, six genes and spots (HLA-DPa, HLA-DQa, HLA-DRb5, SEPT1, EIF2S2 and IDH3A genes, [Fig. 2](#f2-cin-03-399){ref-type="fig"}) show even an improvement for this classification task. The separation of the best and worst quartiles in the three IPI classes is comparable ([Fig. 3](#f3-cin-03-399){ref-type="fig"}) to the prediction success of the complete signature of [@b16-cin-03-399] and classifies different patient quartiles better than the set proposed by [@b9-cin-03-399]; using LMO2, BCL6, FN1, CCND2, SCYA3 and BCL2 for overall survival in DLBCL). Our predictor is delivered by bioinformatical analysis of gene expression measurements, whereas Lossos et al. used real time PCR. However, our method can also be applied to real time PCR data.

Moreover, we tested the influence of the high correlation between the genes HLA-DPa, HLA-DQa and HLA-DRB5 on the quality of the predictor. The survival prediction with predictors of non correlated genes from the univariate analysis yields no improvement in the results (data not shown).

### Genes best distinguishing DLBCL subgroups

Nearest shrunken centroid analysis using the R-package PAM ("Prediction Analysis of Microarrays") identifies best separating genes for the two subgroups (ABC and GCB DLBCL) with smallest cross-validation error ([Fig. S2](#f5-cin-03-399){ref-type="supplementary-material"}). Gene numbers of classifiers are plotted versus the resulting error rates. The optimal classifier ([Table S3](#t5-cin-03-399){ref-type="table"}) requires only 18 genes (31 spots) with an overall cross validation error of 6.2% (5 out of 82 ABC DLBCL samples were falsely predicted as GCB (6.1%); 7 out of 112 GCB DLBCL as ABC (6.25%)). Larger gene sets show similar error rates (see Materials and Methods), smaller gene sets result in inferior classification ([Fig. S2](#f5-cin-03-399){ref-type="supplementary-material"}). GCB DLBCL is correctly predicted even with fewer genes, however, the error for ABC DLBCL samples increases strongly ([Fig. S2](#f5-cin-03-399){ref-type="supplementary-material"} lower plot). For clinical application both entities have to be well separated.

Functional relationship of the genes differently expressed in ABC and GCB
-------------------------------------------------------------------------

### Classical lymphoma gene-markers compared to the identified best separating genes

We tested whether 35 classical lymphoma genes (listed in [Table S4](#t6-cin-03-399){ref-type="table"}; as described in [@b11-cin-03-399]; [@b8-cin-03-399]; [@b27-cin-03-399]; [@b13-cin-03-399]; [@b16-cin-03-399]) separate well the two major subtypes of DLBCL. Three metabolic enzyme genes for LDH (IPI score prognosis marker), IDH and PDH were added. Altogether these 38 genes correspond to 180 spots. PAM analysis identified a set of 9 well classfying genes (21 spots) ([Table S5](#t7-cin-03-399){ref-type="table"} and [S6](#t8-cin-03-399){ref-type="table"}), with an overall error rate of 14% (10% training set; 15% for the validation group). However, the classical genes require more spots and their separation is not as good as the optimal prediction set above ([Fig. S2](#f5-cin-03-399){ref-type="supplementary-material"}). After this we merged these classical lymphoma marker genes with the best separating gene set found above for classification. We found, however, that here the best separating genes achieve all top ranks in this task ([Table S7](#t9-cin-03-399){ref-type="table"}). Only mitogen-activated protein kinase 10 (MAPK10), the best classical lymphoma marker, reaches top ranks. BCL6 as the next best classical marker reaches only rank 31. Below we show that classical lymphoma genes are close to but not identical to the central regulatory network and genes best separating GCB and ABC DLBCL.

### Cell cycle genes are differently expressed in ABC and GCB

Cell cycle is critical for cancer cell proliferation and we next investigated by PAM analysis (see Material and Methods) whether the functional group of cell cycle genes alone could separate the two B-cell lymphoma groups. We identified 473 spots, which correspond and are homologous to the cell cycle genes found by de Lichtenberg et al. ([@b4-cin-03-399]). These genes are annotated according to expression in the cell cycle state (100 steps between 0 and 99 for a full cell cycle).

The separation between the lymphoma subgroups improves as more genes are used. 77 cell cycle genes ([Table S8](#t10-cin-03-399){ref-type="table"}, [Table S9](#t11-cin-03-399){ref-type="table"}; error rate of 15.4%) yield low error rates using a medium sized gene set (classification optimum, see materials and methods). These include genes such as Butyrophilin-like protein 9 (BTNL9), early B-cell factor (EBF), TSC22 domain family member 1, Cyclin-G2 (CCNG2), Interleukin-6 (IL6), immediate early response protein 5 (IER5) and further homologues of typical cell cycle stage-specific genes ([@b4-cin-03-399]) such as TIMP metallopeptidase inhibitor 1(TIMP1) and v-maf musculoaponeurotic fibrosarcoma oncogene homolog (MAF), which mainly reflect the late cell cycle states. [Figure 3](#f3-cin-03-399){ref-type="fig"} compares the complete cell cycle genes in our data set with the subset of 77 genes in a density plot. The black line indicates all cell cycle states of the whole chip and the blue line the subset of 77 genes. The densities of these gene sets clearly differ in the early (steps 0--18) and in the late steps (75--85) of cell cycle (p = 6.65·10^−10^; Wilcoxon one sided test).

Cell cycle spots, which show the biggest difference in gene expression values between ABC and GCB DLBCL, are in the late steps 72, 80, 84 and 85 ([Fig. S3](#f6-cin-03-399){ref-type="supplementary-material"}; M/A plot, ie,middle intensity of the genes against difference in expression of both lymphoma subgroups). Moreover, these cell cycle states form a compact cluster in the plot. This data indicate a clear difference in cell cycle states regarding the two DLBCL subgroups.

### Cell cycle genes, classical lymphoma genes and best separating genes form a compact network important for DLBCL subtype distinction between ABC and GCB

Are the genes differentially expressed in ABC and GCB DLBCL specially connected, and in particular, if so, how do their respective gene products interact with each other? To analyze this systematically, different large scale protein interaction databases were investigated such as the hand curated HPRD database ([@b12-cin-03-399]). The large proteinprotein interaction database STRING ([@b26-cin-03-399]) allowed us to establish an interaction network ([Fig. S4](#f7-cin-03-399){ref-type="supplementary-material"}, [Fig. S5](#f8-cin-03-399){ref-type="supplementary-material"}). Note that this analysis focuses on the clearly differentially expressed genes in ABC and GCB ([Table S7](#t9-cin-03-399){ref-type="table"}). Classical lymphoma gene markers (dark grey boxes) as listed in [Table S5](#t7-cin-03-399){ref-type="table"} combine and interact with the compact cluster of the most powerful differentiating genes (white boxes) for the whole data set ([Table S3](#t5-cin-03-399){ref-type="table"}) as delivered by PAM. The connections are mainly found by text-mining; however, the two interactions between BCL6---IRF4 and between SH3BP5---MAPK10 are available from the HPRD data set (experimental/biochemical data) as a direct physical interaction (blue). The different article sources re-examine the interaction predictions for different cancer entities: "DLBCL", "no cancer disease" and "other cancer". Note that these categories support the interactions from three different view points ([Fig. S5](#f8-cin-03-399){ref-type="supplementary-material"}). We find that 11 of the 18 best separating genes and 8 of the 9 separating classical lymphoma genes are members of this dense interaction network. This is supported by the interaction data, the HPRD database and various specific interaction evidence types collated by the STRING database.

The remaining 8 genes, 7 from the first mentioned set and 1 from the latter one, are not part of the databases. Cyclin D2 (CCND2) occurs in both subsets and we obtain a protein association network of 18 nodes. Regarding network regulation the underlined genes are higher expressed in ABC, all others are higher expressed in GCB subtype: ASB13, [BCL2]{.ul}, BCL6, BCL7A, [CCND2]{.ul}, COL3A1, CTGF, FN1, [FOXP1]{.ul}, [IGHM]{.ul}, [IRF4]{.ul}, LMO2, LRMP, MAPK10, MME, MYBL1, NEIL1 and [SH3BP5]{.ul} ([Table S10](#t12-cin-03-399){ref-type="table"}). The characteristics of the network are described in [Table 2](#t2-cin-03-399){ref-type="table"}: Protein functions involved in the network include stimulation of proliferation, block of proliferation, apoptosis, differentiation and immune cell specific functions. Both DLBCL subgroups show clear differences in these specific pathways and sub-networks. Furthermore, the large collection of protein associations from the STRING database shows that all these different proteins separating the two subgroups are connected by first order interactions. As a control for this finding of a compact regulatory network separating both entities regarding gene expression, we tested that all Lymphochip genes are equally distributed with regard to the human interactome and not pre-clustered ([Fig. S6](#f9-cin-03-399){ref-type="supplementary-material"}). Moreover, the characteristic path length for randomly picked genes from the Lymphochip is 3.985 ([Fig. S7](#f10-cin-03-399){ref-type="supplementary-material"}) and clearly longer than the direct interactions (path lengths one or two) found for the differentially regulated network ([Fig. S4](#f7-cin-03-399){ref-type="supplementary-material"}).

Moreover, 5 of the 8 cell cycle genes, identified in [Figure S3](#f6-cin-03-399){ref-type="supplementary-material"} above, to be regulated differently are directly interacting with this regulatory network ([Fig. S5](#f8-cin-03-399){ref-type="supplementary-material"}). The genes with a significantly higher expression in the ABC group are marked by a red rectangle, whereas green ellipses mark higher expression in GCB. These differences are an interesting pointer for a more specific anti-cancer treatment.

### Gene functions for well separating genes

The shorter survival of patients with ABC DLBCL is connected to pathways expressed differently from GCB DLBCL; thus the well known BCL2, as a central apoptosis blocker is higher expressed and allows cancer cell survival in ABC DLBCL. BCL6, a transcriptional repressor important for B-cell differentiation, is down-regulated in ABC DLBCL. Altogether, apoptosis genes are lower expressed in the ABC DLBCL subtype.

Furthermore, the low gene expression values of the gene MME, a proliferation blocker, CCND2 and BCL7A, both genes which promote proliferation, and high values of SH3BP5 in the ABC DLBCL patients stimulate proliferation.

Both the immune cell specific genes IGHM and IRF4 are higher expressed in ABC DLBCL; however, all genes which are associated with differentiation are down-regulated.

In conclusion, this network indicates down-regulation of apoptosis and differentiation for the ABC DLBCL patients whereas the proliferation and immune cell stimulating genes are up-regulated.

From the cell cycle genes which are connected to the network, IL6 and IER5 show higher values in the ABC group whereas BTNL9 and CCNG2 show an up-regulation in the GCB group. For the latter it is known that CCNG2 and IL6 block the proliferation.

In order to further validate the found gene expression differences, we show that several of these are found again after analyzing further data from Shipp et al. ([@b18-cin-03-399]; [@b28-cin-03-399]; [Table S12](#t14-cin-03-399){ref-type="table"}).

Do the clear gene expression differences between both subgroups reflect only differences in B-cell specific regulation? In order to gain a first impression regarding T-cell regulatory pathways from our data we tested whether notch genes, trans-membrane receptors important in T cell differentiation and repressed in many cancers ([@b15-cin-03-399]), regulate differently the target genes in the two groups. Target genes are regulated by GY-box-, Brd-box-, and K-box-class microRNAs in the 3′-UTRs e.g. in Drosophila ([@b7-cin-03-399]). We mapped all genes of the Lymphochip to the transcripts annotated in ensembl. We screened these and found candidate notch target genes, whose transcripts bear the mentioned target sequences. All three boxes were found in the genes given in supplementary [Table S11](#t13-cin-03-399){ref-type="table"}. From these transcripts the "Deoxycytidine kinase" gene (ENSG00000156136, DCK) and the "Translocation associated membrane protein 2" (ENSG00000065308, TRAM2) show clear gene expression differences between the ABC and GCB subgroups.

Discussion
==========

Marker genes for DLBCL subtypes
-------------------------------

This study improves marker gene detection for prognosis and subtype diagnosis of diffuse large B-cell lymphomas (DLBCL) applying a wide range of methods useful also for other gene expression measurements in cancer. A special patient group are primary mediastinal B-cell lymphomas. Patients recognized with this disease (6 cases) were excluded from the data set and hence are neither visible nor contained in the further analysis. This is in accordance with previous studies ([@b16-cin-03-399]) and other data sets ([@b1-cin-03-399]; [@b18-cin-03-399]; [@b28-cin-03-399]).

The classification of all other diffuse large B-cell lymphoma into two pathological entities has been established by marker genes and their expression ([@b1-cin-03-399]). A third entity has been discussed ([@b6-cin-03-399]) but was disputed again in the light of recent data. Our statistical analysis by ISIS method ([@b25-cin-03-399]) provides an independent method and validates and supports only these two subgroups. In addition to previous work ([@b16-cin-03-399]), ISIS analysis here clearly indicates for a large data set the bipartition of all patient data into the two subgroups ABC and GCB through an unbiased and independent statistical method. An adequate normalization of the gene expression intensities applying the loess method ([@b29-cin-03-399]; [@b30-cin-03-399]) allowed a better separation for best and worse outcome quartiles of survival, in particular for patients with medium IPI score where a better separation is important for accurate prognosis. We found a simplified (6 instead of 17 gene spots) survival predictor useful for clinical monitoring e.g. applying RT-PCR ([@b10-cin-03-399]). Multivariate analysis showed that a four-spot predictor does not perform well. However, univariate analysis found a six spot prognosis predictor which is superior to a previous six-spot predictor (Lossos et al. 2004) and to an alternative five spot predictor, in particular regarding high risk patients.

Integrated picture of all gene regulation differences
-----------------------------------------------------

Following this, the statistical analysis identified all genes which well distinguish the ABC and GCB DLBCL subgroups including differences in early and late cell cycle which could be exploited for a differential cytostatic therapy in the two subgroups.

We considered all the identified gene expression differences in order to obtain a detailed description of the differences between both DLBCL subgroups regarding regulation of the cellular network. We show that immune signatures, apoptotic and proliferation pathways are tuned in different ways between ABC and GCB DLBCL. A central circuit of genes is formed by genes that distinguish both lymphoma subgroups and are regulated differently. We also verified this for other data after completion of the first analysis. For the data in [@b18-cin-03-399] and [@b28-cin-03-399] once again key genes from the central network shown in [Figure S4](#f7-cin-03-399){ref-type="supplementary-material"} are confirmed as having a significant different regulation in this totally different data and patient set ([Table S12](#t14-cin-03-399){ref-type="table"}). Classical lymphoma genes are either directly or indirectly interacting with it. Besides this central network other pathways are also implicated, we showed that two Notch pathway targets are specifically up-regulated. PAM has been shown previously to be a powerful method for gene selection ([@b24-cin-03-399]).

The different predictors shown in this study were the best predictors according to PAM curves and statistical analysis and gave clear improvements for prognosis prediction compared to previous studies ([@b16-cin-03-399]; [@b9-cin-03-399]) including a six spot predictor for clinical application. Furthermore, our results are based on experimental gene expression data on 248 patients and individual analysis of 12196 array spots whereas pooled data and fewer patients were used in older studies ([@b16-cin-03-399]; [@b9-cin-03-399]). Interesting marker genes were found in this study by different statistical methods (PAM, ISIS, LIMMA). Clearly, using other methods (e.g. support vector machines) different gene sets can be obtained. In our study, the ISIS method is applied for explorative analysis and unbiased classification without prior knowledge or gene signatures. It supports independently the two distinct B-cell lymphoma subgroups. The different gene sets were further validated against each other by including classical marker genes. Moreover, we validate in our study key marker genes we found by analysis of additional and further data ([@b18-cin-03-399]; [@b28-cin-03-399]). A new perspective from this study is that genes found differently expressed in the two B-cell lymphoma types form a compact interaction network including cell cycle genes. This is obtained by another independent analysis method (protein-protein interaction database STRING). Furthermore, the delineated regulatory network adds biological data and data from large-scale interaction databases to show that the identified marker genes are in fact members of a closely interacting regulatory network, with molecular functions that mirror the differences in pathology of the two subgroups GCB and ABC DLBCL.

The identification of cell cycle genes expressed differently indicates here new possible targets for therapy. Differences between the ABC and GCB DLBCL subgroups are at the beginning and the end of the M-phase and the early part of the G1 phase. Inhibiting early cell cycle genes, overexpressed in ABC and adding known cytostatic drugs such as mitosis inhibitors and early G1 blocker may be particularly useful for ABC DLBCL patients. A more detailed therapy profile would take the further differences in regulation into account.

Conclusion
==========

The present analysis reveals through the use of an array of methods a detailed picture of molecular markers differentiating cancer subtypes. We apply it to GCB and ABC DLBCL for clinical use in determining prognosis and diagnosis. This included efficient six spot predictors for prognosis and clinical application. The entities ABC and GCB DLBCL have been confirmed by statistical analysis independent of gene expression signatures, a third entity could not be supported. The resulting genes with altered expression were found to form a tightly connected regulatory network including cell cycle genes, apoptosis and immune differentiation implicated in the aggressive behaviour of ABC DLBCL compared to the GCB DLBCL subtype.

Supplemental Methods
====================

To systematically identify spots which describe the outcome and cooperate well with each other in the Cox regression hazard model a multivariate analysis is desirable. However, this requires a huge search space of combinations to be tested. To reduce this we considered only four spot combinations of (i) the gene spots suggest by Rosenwald et al. ([@b16-cin-03-399]), (ii) the 36 important genes for diffuse large B-cell lymphoma chosen by Lossos et al. ([@b9-cin-03-399]) or (iii) the LDH-, IDH-, and PDH gene spots (the latter to better reflect IPI-scores). Cox Regression Hazard analysis was performed on all possible four tuples of these 153 indicator spots testing 160 patients (several days of calculation time on a LINUX cluster with 20 nodes of Pentium IV CPUs). [Table S1](#t3-cin-03-399){ref-type="table"} shows the gene content of the ten best multivariate four-spot-predictors (the next best combinations after removing these spots is found in [Table S2](#t4-cin-03-399){ref-type="table"}). The best multivariate four-spot combination is compact and small, but neither as good as the five spot predictor in results nor as the signatures from Rosenwald et al. ([@b16-cin-03-399]). The analysis further shows that there is a correlation with survival prediction for the clinical parameter LDH ([Table S2](#t4-cin-03-399){ref-type="table"}), but the prediction based on this well known parameter (part of the IPI score) is even worse then the results shown in [Table S2](#t4-cin-03-399){ref-type="table"}.

In contrast (see below), the new five-spot and six-spot predictors identified by univariate analysis will be useful heuristics for diagnosis and clinic, e.g. to identify risk quartiles and subgroups ([Fig. S1](#f4-cin-03-399){ref-type="supplementary-material"}).

###### **Kaplan Meier plots of the IPI groups.** The Kaplan Meier plots estimated by the molecular predictor of Rosenwald et al. ([@b16-cin-03-399]) applied on the new normalized gene expression data of the 240 diffuse large B-cell lymphoma patients. The plots show different groups according to their IPI risk and the training set as Training, Validation and all patients. The left column represents the training-group, the middle one the validation group and the right one all patients. The rows show the IPI risk groups. The first line shows low risk, the second one the medium risk and the last line the high risk patients. The x-axis is the time in years and the y-axis the probability of survival.

###### **PAM misclassification error of the ABC and GCB subgroups over all genes.** The upper plot shows the overall error while the lower one shows the subgroup specific errors. In both, the various thresholds on the lower x-axis correspond to different numbers of genes, labelled on the upper x-axis. The y-axis represents the error and ranges from 0 to 1. The good overall performance of PAM requires only few genes to decrease the error dramatically. The error rate decreases strongly between the thresholds of 6 and 5, which represent the amount of shrinkage. Hence we chose a threshold below 5 with the corresponding set of best separating genes (an optimal choice with few errors and a low number of genes). The performance for the single subgroups shows a big difference between ABC and GCB. Whereas GCB shows a good performance even with few genes, the prediction quality of ABC decreases dramatically in the case of ABC patients. This indicates a complex pattern of gene expression in ABC patients which is defined in more than 15 genes.

###### **Cell cycle genes with extreme expression differences shown by a MA-plot of normalized gene expression values.** The M values on the y-axis correspond to the gene expression difference between the ABC and GCB patient medians and the A values on the x-axis correspond to the average expression of all genes in both groups. The colored points represent the 77 cell cycle spots chosen by PAM analysis. The color scale ranges from yellow to red, whereas yellow is annotated to cellcycle state 0 and red to state 99. Additionally some cell cycle genes show more extreme A values(circle). They are labeled with their names and their cell cycle state. Remarkably, some genes associated with a late high cell cycle state cluster together regarding their gene expression values in both dimensions (ellipse). Again, late cell cycle states indicate a high difference in the M-value (difference in gene expression) between the two subgroups. A locally weighted regression smoothing line (lowess) shows that systematic and random variations are well controlled by the normalization procedure: Its shape fits almost perfectly the horizontal line.

###### **Regulatory network differently regulated in ABC and GCB B-cell lymphomas.** This figure shows the resulting network and interaction pattern with each other for the best separating genes applying data from the STRING meta-database of protein interactions. Classical lymphoma genes and best separating gene set form a tight network with the best separating genes in the centre. Shown are the strongly connected network members. They consist of (i) classical lymphoma marker genes (grey boxes), and (ii) the most powerful predictive genes in the PAM analysis (white boxes). Genes which show a significant higher expression in the ABC subgroup are marked by a red rectangle. They are associated to proliferation, block of proliferation, apoptosis, differentiation and specific for immune cells, as most of the remaining ones. Green ellipses mark higher expression in GCB. The almost fully connected gene network demonstrates that both classes of genes are well participating in the interaction network according to the STRING meta-database. Furthermore, the STRING analysis shows that almost all connections between both classes -- the yellow colored edges - are based on literature (mainly Medline reports). Only the interaction of "interferon regulatory factor 4" (IRF4) and "B-cell CLL/lymphoma 6" (BCL6) is confirmed by large-scale interaction screen experiments.

###### **Regulatory network differently regulated in ABC and GCB B-cell lymphomas.** Functional protein association network using interactions predicted by the STRING database: the most powerful predictive genes in the PAM analysis (white boxes; see [Figure 4S](#f4-cin-03-399){ref-type="supplementary-material"}), classical textbook lymphoma genes (dark grey boxes), additional the cell cycle genes (light grey boxes; see [Figure 3S](#f3-cin-03-399){ref-type="fig"}: 5 of these 8 cell cycle genes are connected directly with the network. TIMP1 even connects the so far uninvolved classical lymphoma gene CTGF with the network. This indicates how well the cell cycle genes fit to the existing graph). The new connections are confirmed by text mining of PubMed abstracts(circles: DLBCL, diamonds: "no cancer disease", empty square: "other cancer"); these different data complement each other. The genes with a significantly higher expression in the ABC group are marked by a red rectangle. Green ellipses mark higher expression in GCB. Black hexagons mark genes which have a very high average gene expression value in both entities and are an important part for the network.

###### **The Lymphochip genes in the human interactome.** This plot shows the human interactome as a protein interaction network. The proteins(circles) of the lymphochip are filled out. Interactions are drawn as a line. Characteristic path length and the longest path are 4.642 and 15, respectively.

###### **Histogram of the protein interaction distances.** The genes of the Lymphochip were mapped to the protein interaction graph in the human interactom. The histogram shows the occurring distances of these genes in the interactome. The longest distance is 11 whereas the characteristic path length is 3.985.

###### 

Multivariate Cox regression hazard models.

  **Nr**   **Multivariate Cox regression hazard model**                            
  -------- ---------------------------------------------- ----------- ------------ ---------
  1        HGAL                                           Germ-S      ACTa1        HLA-DRA
  2        HGAL                                           CD54(2)     ACTa1        HLA-DRA
  3        HGAL                                           CD54(2)     HLA-DRA(2)   ACTa1
  4        HGAL                                           CD54(2)     HLA-DRA(3)   ACTa1
  5        HGAL                                           ACTa1       HLA-DRA      CD54
  6        HGAL                                           MHCIIDQa1   CD54(2)      ACTa1
  7        HGAL                                           CD54(2)     MHCIIDRb     ACTa1
  8        HGAL                                           Germ-S      MHCIIDRb     ACTa1
  9        HGAL                                           Germ-S      HLA-DRA(2)   ACTa1
  10       HGAL                                           Germ-S      HLA-DRA(3)   ACTa1

A heuristic search of multivariate Cox regression hazard models revealed this 10 best fitting models. All possible multivariate Cox regression hazard models of four 4 genes from 36 important genes for diffuse large B-cell lymphoma and the metabolic genes LDH, IDH and PDH were calculated and these ten gene sets fit best. Genes are abbreviated according to GenBank nomenclature.

###### 

Next best multivariate Cox regression hazard models.

  **Nr.**   **Multivariate Cox regression hazard model**                        
  --------- ---------------------------------------------- --------- ---------- ----------
  1         CD10                                           IRF4      HLA-DRb5   LDH(2)
  2         IRF4(2)                                        BCL7A     HLA-DRb5   LDH(2)
  3         MYC                                            IRF4(2)   HLA-DRb5   LDH
  4         MYC                                            IRF4(2)   HLA-DQa1   LDH
  5         PLAU                                           IRF4      BCL7A      HLA-DRb5
  6         IRF4                                           BCL7A     HLA-DRb5   LDH(2)
  7         PLAU                                           IRF4(2)   BCL7A      HLA-DRb5
  8         IRF4                                           BCL6      BCL7A      HLA-DRb5
  9         CD10                                           IRF4(2)   HLA-DRb5   LDH(2)
  10        MYC                                            IRF4(2)   HLA-DRb5   LDH(2)

If the genes appearing in [Table S1](#t3-cin-03-399){ref-type="table"} are removed, and the heuristic search of multivariate Cox regression hazard models is redone, these ten models are the next best fitting. The genes are represented by their GenBank abbreviation. The metabolic marker LDH from the IPI score occurs in the four best fitting models as well as in the the majority of the models.

###### 

Genes which distinguish best between ABC and GCB according PAM analysis.

  **Nr.**   **Gene**
  --------- ---------------------------------------------------------
  1         MYBL1
  2         \*Centerin
  3         FOXP1
  4         LOC96597
  5         SH3BP5
  6         KIAA0864
  7         IRF4
  8         ASB13
  9         \*Similar to human endogenous retrovirus-4 Clone=417048
  10        NEIL1
  11        MME
  12        IGHM
  13        LMO2
  14        LOC152137
  15        KIAA1039
  16        LRMP
  17        FLJ123633
  18        CCND2

From all twelve thousand spots from the lymphoma chip, the listed genes distinguish best between ABC and GCB according to PAM analysis. The best separating genes are written on the top.

###### 

Classical lymphoma genes.

  **Nr.**   **Gene**
  --------- ---------------------------------
  1         BCL6
  2         BRAF
  3         ARAF1
  4         RAF1
  5         RAS
  6         MEK
  7         MAP
  8         HLA-DPα
  9         HLA-DQα
  10        HLA-DRα
  11        HLA-DRβ
  12        α-Actinin
  13        COL3A1
  14        Connective-tissue growth factor
  15        FN1
  16        KIAA0233
  17        PLAUR
  18        E2IG3
  19        NPM3
  20        BMP6
  21        CASP10
  22        POU2AF1
  23        CDKN2A
  24        MYC
  25        BCL2
  26        FCGR2B
  27        CyclinD1
  28        NFKB2
  29        PAX5
  30        BCL10
  31        CDK6
  32        DDX6
  33        BCL7A
  34        CyclinD2
  35        IL-10
  36        LDH
  37        IDH
  38        PDH

Lymphoma associated genes were collected from literature and were also found in the data set. Furthermore we added the metabolic enzymes "lactate dehydrogenase"(LDH), "isocitrate dehydrogenase" (IDH) and "pyruvate dehydrogenase"(PDH). The latter are represented in the data by the genes PDHB, PDHA1, IDH3A, IDH3G, IDH3B, IDH1, IDH3B, IDH3A, LDHB and LDHA.

###### 

Classical marker genes of lymphoma disease distinguish between ABC and GCB lymphoma subtype (PAM analysis; error rates for this gene set: TR:10% VAL:15.38%; F:CV:14%))

  **Nr.**   **Gene**
  --------- ----------
  1         FN1
  2         BCL6
  3         CTGF
  4         BCL2
  5         MAPK10
  6         CCND2
  7         COL3A1
  8         KIAA0233
  9         BCL7A

###### 

Lymphochip spots of known lymphoma genes.

  **SpotID**   **Gene Name**
  ------------ ---------------
  19384        MAPK10
  24787        CCND2
  15914        MAPK10
  24429        BCL6
  28472        MAPK10
  19268        BCL6
  16858        CCND2
  17646        BCL2
  16789        BCL2
  19361        COL3A1
  26535        BCL6
  28859        BCL2
  24367        BCL2
  17791        FN1
  16016        FN1
  16732        FN1
  31398        FN1
  19379        FN1
  27499        KIAA0233
  24415        BCL7A
  29222        CTGF

180 spots, which are known to deal with lymphoma were tested to distinguish between ABC and GCB subtype by PAM analysis. Successful genes are given in descending order (gene set error rate:TR:10% VAL:15.38%; F:CV:14%)

###### 

Combined classifier for lymphoma subtypes.

  **SpotID**   **Gene Name**
  ------------ -----------------------------------------------
  24376        \*Centerin
  17496        MYBL1
  28014        MYBL1
  19326        IGHM
  19254        MME
  33991        FOXP1
  19384        MAPK10
  19375        FOXP1
  16049        IGHM
  26454        SH3BP5
  22118        KIAA0864
  24787        CCND2
  24787        CCND2
  28979        LMO2
  15914        MAPK10
  19346        SH3BP5
  15864        MME
  19238        LMO2
  30263        ASB13
  19291        MYBL1
  19312        NEIL1
  25036        FLJ12363
  26385        MME
  19227        LOC96597
  22122        IRF4
  16886        LRMP
  24480        KIAA1039
  27378        LRMP
  27379        LRMP
  24729        IRF4
  27673        LRMP
  19348        \*Similar to
  24429        BCL6
  28472        MAPK10
  26516        \*Similar clone=417048
  19268        BCL6 \@Homo sapiH08 (LOC152137) Sur_clone=232
  32529        2321
  17646        BCL2

The resulting gene list that distinguishes ABC and GCB if the PAM analysis is performed only on the 31 best spots merged with the well known lymphoma genes. Marked in grey are the 31 best spots from all twelve thousand spots compared. Remarkably, the two classical lymphoma marker genes MAPK10 and CCND2 reach a similar quality in distinguishing ABC and GCB as the best separating ones.

###### 

Cell cycle gene set that best distinguishes ABC and GCB subgroup. The genes are annotated by their spot ID, ensembl gene-ID and their gene name. Additionally the cell cycle states are given. The latter parameter shows a strong signal in the early and late cell cycle states compared with all available cell cycle states in the data set.

  **SpotID**   **Ensembl ID**    **cell cycle state**   **Gene**
  ------------ ----------------- ---------------------- -----------
  24927        ENSG00000165810   85                     BTNL9
  33929        ENSG00000165810   85                     BTNL9
  26913        ENSG00000138764   72                     CCNG2
  24750        ENSG00000136244   80                     IL6
  32430        ENSG00000162783   56                     IER5
  24491        ENSG00000165810   85                     BTNL9
  30172        ENSG00000138764   72                     CCNG2
  24930        ENSG00000187837   69                     HIST1H1C
  24725        ENSG00000011007   59                     TCEB3
  24908        ENSG00000118515   83                     SGK
  30355        ENSG00000164330   84                     EBF
  32096        ENSG00000164330   84                     EBF
  31931        ENSG00000164543   18                     STK17A
  26081        ENSG00000180447   80                     GAS1
  19374        ENSG00000124762   21                     CDKN1A
  24969        ENSG00000164330   84                     EBF
  24647        ENSG00000164330   84                     EBF
  34708        ENSG00000118515   83                     SGK
  27774        ENSG00000134058   92                     CDK7
  26401        ENSG00000118515   83                     SGK
  26725        ENSG00000164330   84                     EBF
  28881        ENSG00000163918   52                     RFC4
  17786        ENSG00000102804   1                      TSC22D1
  24613        ENSG00000102804   1                      TSC22D1
  33901        ENSG00000100644   2                      HIF1A
  27538        ENSG00000171656   96                     ETV5
  27952        ENSG00000179583   76                     CIITA
  34557        ENSG00000052841   2                      TTC17
  30021        ENSG00000099953   95                     MMP11
  27704        ENSG00000164330   84                     EBF
  26992        ENSG00000102804   1                      TSC22D1
  26344        ENSG00000138764   72                     CCNG2
  24832        ENSG00000163918   52                     RFC4
  26080        ENSG00000163739   76                     CXCL1
  33329        ENSG00000179583   76                     CIITA
  17290        ENSG00000134058   92                     CDK7
  30922        ENSG00000185658   5                      BRWD1
  26162        ENSG00000135541   91                     AHI1
  34288        ENSG00000134884   48                     NA
  33646        ENSG00000185658   5                      BRWD1
  26951        ENSG00000102804   1                      TSC22D1
  24977        ENSG00000153936   92                     HS2ST1
  16661        ENSG00000123080   75                     CDKN2C
  25942        ENSG00000145050   49                     ARMET
  22163        ENSG00000169926   6                      KLF13
  17405        ENSG00000178573   30                     MAF
  27275        ENSG00000100644   2                      HIF1A
  30415        ENSG00000164330   84                     EBF
  34484        ENSG00000151150   50                     ANK3
  33221        ENSG00000065809   2                      FAM107B
  32218        ENSG00000179583   76                     CIITA
  29637        ENSG00000145632   99                     PLK2PLK2
  27939        ENSG00000179583   76                     CIITA
  27328        ENSG00000108984   44                     MAP2K6
  28792        ENSG00000099326   53                     ZNF42
  30725        ENSG00000175455   65                     CCDC14
  16736        ENSG00000136244   80                     IL6
  30874        ENSG00000081320   77                     STK17B
  28707        ENSG00000123080   75                     CDKN2C
  33336        ENSG00000175455   65                     CCDC14
  15871        ENSG00000168310   7                      IRF2
  28640        ENSG00000100526   0                      CDKN3
  28748        ENSG00000136244   80                     IL6
  28430        ENSG00000168310   7                      IRF2
  26084        ENSG00000128590   38                     DNAJB9
  30859        ENSG00000117650   93                     NEK2
  28674        ENSG00000138061   66                     CYP1B1
  16127        ENSG00000138061   66                     CYP1B1
  24868        ENSG00000012963   52                     C14orf130
  30508        ENSG00000081320   77                     STK17B
  34108        ENSG00000169926   6                      KLF13
  16053        ENSG00000173757   83                     STAT5B
  16091        ENSG00000100526   0                      CDKN3
  33594        ENSG00000179583   76                     CIITA
  32924        ENSG00000185658   5                      BRWD1
  32766        ENSG00000135164   74                     DMTF1
  16597        ENSG00000109971   0                      HSPA8

###### 

The cell cycle genes, which were chosen to distinguish the ABC and the GCB group.

  **Ensembl gene ID**   **cell cycle state**   **Gene symbol**
  --------------------- ---------------------- -----------------
  ENSG00000011007       59                     TCEB3
  ENSG00000012963       52                     C14orf130
  ENSG00000052841       2                      TTC17
  ENSG00000065809       2                      FAM107B
  ENSG00000081320       77                     STK17B
  ENSG00000099326       53                     ZNF42
  ENSG00000099953       95                     MMP11
  ENSG00000100526       0                      CDKN3
  ENSG00000100644       2                      HIF1A
  ENSG00000102804       1                      TSC22D1
  ENSG00000108984       44                     MAP2K6
  ENSG00000109971       0                      HSPA8
  ENSG00000117650       93                     NEK2
  ENSG00000118515       83                     SGK
  ENSG00000123080       75                     CDKN2C
  ENSG00000124762       21                     CDKN1A
  ENSG00000128590       38                     DNAJB9
  ENSG00000134058       92                     CDK7
  ENSG00000134884       48                     NA
  ENSG00000135164       74                     DMTF1
  ENSG00000135541       91                     AHI1
  ENSG00000136244       80                     IL6
  ENSG00000138061       66                     CYP1B1
  ENSG00000138764       72                     CCNG2
  ENSG00000145050       49                     ARMET
  ENSG00000145632       99                     PLK2PLK2
  ENSG00000151150       50                     ANK3
  ENSG00000153936       92                     HS2ST1
  ENSG00000162783       56                     IER5
  ENSG00000163739       76                     CXCL1
  ENSG00000163918       52                     RFC4
  ENSG00000164330       84                     EBF
  ENSG00000164543       18                     STK17A
  ENSG00000165810       85                     BTNL9
  ENSG00000168310       7                      IRF2
  ENSG00000169926       6                      KLF13
  ENSG00000171656       96                     ETV5
  ENSG00000173757       83                     STAT5B
  ENSG00000175455       65                     CCDC14
  ENSG00000178573       30                     MAF
  ENSG00000179583       76                     CIITA
  ENSG00000180447       80                     GAS1
  ENSG00000185658       5                      BRWD1
  ENSG00000187837       69                     HIST1H1C

The cell cycle genes annotated by their ensembl gene-ID and their gene name. Additionally the cell cycle states are annotated. The latter parameter shows a strong signal in the early and late cell cycle states compared with all available cell cycle states in the data set.

###### 

Gene expression values of the main regulatory network distinguishing ABC and GCB.

  **Gene**   **ABC**   **GCB**
  ---------- --------- ---------
  ASB13      −         \+
  MYBL1      −         \+
  MME        −         \+
  MAPK10     −         \+
  LRMP       −         \+
  LMO2       −         \+
  FN1        −         \+
  CTGF       −         \+
  COL3A1     −         \+
  BCL6       −         \+
  BCL7A      −         \+
  NEIL1      −         \+
  SH3BP5     \+        −
  BCL2       \+        −
  CCND2      \+        −
  IRF4       \+        −
  IGHM       \+        −
  FOXP1      \+        −

Genes from [Figure 2](#f2-cin-03-399){ref-type="fig"} and their gene expression values in the subgroups ABC and GCB are shown. The symbol "−" indicates a lower gene expression than "+". In this network, more genes of the more aggressive ABC type have a lower gene expression than the GCB type.

###### 

List of potential Notch target transcripts.

  **Gene ID**       **Transcript ID**   **Description**
  ----------------- ------------------- ---------------------------------------------
  ENSG00000156136   ENST00000286648     Deoxycytidine kinase
  ENSG00000148158   ENST00000277244     Sorting nexin family member 30
  ENSG00000179388   ENST00000317216     Early growth response protein 3
  ENSG00000198833   ENST00000361212     Ubiquitin-conjugating enzyme E2 J1
  ENSG00000198833   ENST00000361333     Ubiquitin-conjugating enzyme E2 J1
  ENSG00000065308   ENST00000182527     Translocation associated membrane protein 2
  ENSG00000170584   ENST00000302764     NudC domain containing protein 2
  ENSG00000074706   ENST00000265198     phosphoinositide-binding protein PIP3-E
  ENSG00000134108   ENST00000256496     ADP-ribosylation factor-like 10C)

For all genes of the Lymphochip, all available transcripts annotated in ensembl were screened for the GY, Brd and K boxes. Only these transcripts bear all three boxes, GY, Brd and K in the 3′-UTRs. They are possible candidates to be regulated by the Notch signalling pathway. Moreover, the Deoxycytidine kinase (ENSG00000156136) and the Translocation associated membrane protein 2 (ENSG00000065308) show different gene expression values between the ABC and GCB subgroups.

###### 

T-test result of network genes in another data set.

  **Genes**   **P-value**    **T-value**
  ----------- -------------- -------------
  CCND2       6.260705e-06   5.56939706
  BCL6        2.490035e-02   −2.34449786
  BCL2        1.843571e-03   3.43618678
  IRF4        2.082072e-07   6.49044833
  LMO2        3.820841e-07   −6.66162303
  MAPK10      3.888633e-02   −2.15403094

The genes from the proposed STRING-network in [Figure 4](#f4-cin-03-399){ref-type="supplementary-material"} were used to apply a T-test between the ABC and the GCB group in the gene expression data of Shipp et al. The authors Wright et al. found some evidence for these DLBCL groups in there. The most obvious rejection of the null hypothesis is delivered by IRF4, LMO2, CCND2, BCL2, BCL6 and MAPK10, which are also part of the predictor of Wright et al.
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![**DLBCL splits into sub-groups independent of signatures.** Optimal bipartitions of patients are calculated by ISIS based on optimal bipartition subsets of genes (50). Every column of the x-axis represents a patient. On the bottom, the DLBCL-type of the patient is labelled. On the y-axis every row shows the bipartitions ranked in increasing score of separation quality. The three best bipartitions show a very consistent and clear signal separating the ABC- from the GCB-patients. The unsupervised method ISIS reveals the ABC-GCB classification independent of proliferation signatures. No evidence for a previously suggested third group "Type 3" was found. Only a few patients are falsely assigned if compared to the DLBCL gene signature assignment.](CIN-03-399-g001){#f1-cin-03-399}

![**Prognosis prediction applying a molecular predictor of 6 gene spots after improved normalization.** Kaplan-Meier plots show large differences in the survival rate for all risk groups. They are estimated by a Cox-Regression Hazard model of the genes listed in [Table 1](#t1-cin-03-399){ref-type="table"}. Normalization was improved applying the "loess" method. x-axis: time (years); y-axis: probability of survival, predicted for the risk groups "low", "medium" and "high".](CIN-03-399-g002){#f2-cin-03-399}

![**Early and late cell cycle genes are overrepresented in the best separating cell cycle gene set.** The density plot compares the distribution of different cell cycle gene sets. x-axis: cell cycle states (from 0 to 99; complete cell cycle). y-axis: relative frequencies. Black line: density of all mapped cell cycle genes of de Lichtenberg et al ([@b4-cin-03-399]) in the data set. The area under this line is coloured for easier comparison. Blue line: Optimal separating subset of cell cycle genes (77 spots). Two peaks in the early and late cell cycle states show cell cycle gene expression differences between the subgroups ABC and GCB.](CIN-03-399-g003){#f3-cin-03-399}

###### 

Optimal molecular survival predictor applying six genes.

  **Gene name**   **Gene description**
  --------------- -----------------------------------------------------------------------
  HLA-DPa         Major histocompatibility complex, class II, DP alpha 1
  HLA-DQa         Major histocompatibility complex, class II, DQ alpha1
  HLA-DRb5        Major histocompatibility complex, class II, DR beta 1
  SEPT1           Serologically defined breast cancer antigen NY-BR-24=Similar to DIFF6
  EIF2S2          Eukaryotic translation initiation factor 2 subunit 2
  IDH3A           Isocitrate dehydrogenase 3 (NAD+) alpha

The gene symbol (left side) is followed by the gene description. Three of these genes are HLA major histocompatibility complex genes (HLA).

###### 

Regulatory network of genes best distinguishing ABC and GCB.

  **Functional categories**   **Gene**                                                                                                                                                                                                                       **Description**
  --------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ --------------------------------------------------------------------------------------------------------------------------------
  Proliferation               CCND2                                                                                                                                                                                                                          cyclin D2, regulates G1 to S transition of CDK4/CDK6; CTGF, fibroblast growth factor
  MAPK10                      map kinase 10                                                                                                                                                                                                                  
  MYBL1                       transcriptional activator in the proliferation of neurons, spermatogenic and B-lymphoid cells (recognition sequence: 5′YAAC(GT)G-3′)                                                                                           
  ASB13                       ankyrin repeat and sox box-containing protein 13, mediates protein-protein interactions, sox box couples suppressors of cytokine signalling and binding partners with elongin B and C complex to target them for degradation   
  SH3BP5                      SH3 domain binding protein, targets protein-protein interaction                                                                                                                                                                
  Block of proliferation      MME                                                                                                                                                                                                                            synonyms CALLA, common acute lymphocytic leukemia antigen, the synonym CD10 stresses its properties as a tumor suppressor gene
  BCL7A                       putative tumor suppressor gene in T-cell lymphoma                                                                                                                                                                              
  Apoptosis                   BCL2                                                                                                                                                                                                                           integral outer mitochondrial protein to block apoptosis
  BCL6                        transcriptional repressor, necessary for germinal center formation in lymph nodes                                                                                                                                              
  Differentiation             CTGF                                                                                                                                                                                                                           fibroblast differentiation
  FOXP1                       forkhead box P1                                                                                                                                                                                                                
  LMO2                        LIM domain only 2 transcription factor for hematopoetic development                                                                                                                                                            
  LAMP                        expressed in lymphoid cells during development                                                                                                                                                                                 
  COL3A1                      collagen type III                                                                                                                                                                                                              
  FN1                         fibronectin 1, cell adhesion                                                                                                                                                                                                   
  NEIL1                       base excision repair                                                                                                                                                                                                           
  Immune cell specific        IGHM                                                                                                                                                                                                                           immunoglobulin heavy chain gene
  IRF4                        interferon regulatory factor 4                                                                                                                                                                                                 

The genes of the network in [Figure 4](#f4-cin-03-399){ref-type="supplementary-material"} (suppl.) are associated to the functional categories "Proliferation", "Block of proliferation", "Apoptosis", "Differentiation" and "Immune cell specific", by their annotation. Most of them are part of the antagonists "Proliferation" and "Block of proliferation". This indicates the complex regulation and importance of proliferation in the determination of ABC and GCB lymphomas. Classical lymphoma genes (see [Table S4](#t6-cin-03-399){ref-type="table"}) known previously are given in *italics*.
